Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 40 Neoplasm Metastasis 7 Leiomyosarcoma 7 Liposarcoma 6 Hemangiosarcoma 6 Neurofibrosarcoma 5 Sarcoma, Synovial 4 Osteosarcoma 4 Histiocytoma, Malignant Fibrous 4 Glioblastoma 4 Dermatofibrosarcoma 4 Chondrosarcoma, Extraskeletal Myxoid 4 Sarcoma, Alveolar Soft Part 3 Neoplasms 3 Gliosarcoma 3 Gastrointestinal Stromal Tumors 3 Fibrosarcoma 3 Breast Neoplasms 3 Brain Neoplasms 3 Solitary Fibrous Tumors 2 Sarcoma, Clear Cell 2 Rhabdomyosarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Nerve Sheath Neoplasms 2 Histiocytoma, Angiomatoid Fibrous 2 Hemangioendothelioma, Epithelioid 2 Granuloma, Plasma Cell 2 Carcinoma, Renal Cell 2

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 avapritinib 1 Surgical Procedures, Operative 1 Imatinib Mesylate 1 Coal Tar 1 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

GIST × pazopanib × Sarcoma × Clear all

NCT01323400 2016-02-25

PAZOGIST

Centre Leon Berard

Phase 2 Completed

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡